NASDAQ$GOSS
Gossamer Bio Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Announced financial results for the second quarter 2020 and provided a corporate update.
Gossamer Bio reported a net loss of $66.9 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $600.4 million as of June 30, 2020, which is expected to fund operations into 2024.
- Phase 2 studies for GB001 in eosinophilic asthma and chronic rhinosinusitis are on track for topline data readout in the second half of 2020.
- Phase 2 TORREY study for GB002 in pulmonary arterial hypertension is expected to commence in the second half of 2020.
- Phase 2 SHIFT-UC study for GB004 in ulcerative colitis is expected to commence in the second half of 2020.
- Cash, cash equivalents, and marketable securities totaled $600.4 million as of June 30, 2020.
Headline financials
Revenue & EPS history
Gossamer Bio · Revenue · Quarterly
$253K
Revenue by segment
Gossamer Bio · $17M total across 1 segment · Q1 2026
- Collaborators$17M—100.0%
Forward guidance
Gossamer Bio anticipates several milestones across its clinical programs and expects current resources to fund operations into 2024.
Tailwinds
- Phase 2b LEDA study in eosinophilic asthma on track for topline data in H2 2020
- Phase 2 TITAN study in chronic rhinosinusitis on track for topline data in H2 2020
- Phase 2 TORREY study in pulmonary arterial hypertension expected to commence in H2 2020
- Phase 2 SHIFT-UC study in ulcerative colitis expected to commence in H2 2020
- Further Phase 1 data from KEYNOTE-A36 expected in Q4 2020
Headwinds
- COVID-19 related delays in study enrollment for GB002
- Potential delays in commencement, enrollment, and completion of clinical trials
- Dependence on third parties for manufacturing, research, and testing
- Risk of unexpected adverse side effects or inadequate efficacy of product candidates
- Potential for using capital resources sooner than expected
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
13 / 30 earnings
Positive
+15.2%
Q4 2022
Best reaction
-15.6%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -34.9% | -50.9% | |
| Q4 2025 | -10.8% | -21.0% | -5.5% | |
| Q3 2025 | +2.2% | +16.9% | +44.2% | |
| Q2 2025 | -8.5% | -18.9% | +15.7% | |
| Q1 2025 | +1.0% | +9.5% | +18.1% | |
| Q4 2024 | +0.0% | +6.0% | -38.4% | |
| Q3 2024 | -0.9% | -4.4% | -15.1% | |
| Q2 2024 | +4.3% | +7.5% | +12.5% | |
| Q1 2024 | -3.2% | -5.0% | -23.2% | |
| Q4 2023 | +4.1% | -4.8% | -26.2% | |
| Q3 2023 | -12.0% | +4.7% | +73.1% | |
| Q2 2023 | -7.0% | -9.3% | -24.7% | |
| Q1 2023 | +3.7% | -11.8% | -7.4% | |
| Q4 2022 | +15.2% | +5.7% | -0.5% | |
| Q3 2022 | -0.8% | -4.2% | -14.9% | |
| Q2 2022 | +4.6% | +6.5% | +13.7% | |
| Q1 2022 | +12.5% | +34.2% | +9.5% | |
| Q4 2021 | +3.7% | +1.0% | -2.8% | |
| Q3 2021 | -1.4% | -9.1% | -16.6% | |
| Q2 2021 | -0.8% | +9.5% | +18.9% | |
| Q1 2021 | -0.7% | -0.7% | +1.7% | |
| Q4 2020 | -9.4% | -5.5% | -11.6% | |
| Q3 2020 | -0.9% | -1.3% | +4.2% | |
| Q2 2020 | +5.1% | +2.4% | -1.1% | |
| Q1 2020 | -15.6% | -11.5% | -27.8% | |
| Q4 2019 | +5.5% | +5.7% | +40.0% | |
| Q3 2019 | -4.3% | -1.2% | +12.4% | |
| Q2 2019 | -2.5% | +3.2% | +2.6% | |
| Q1 2019 | +1.3% | +3.7% | -3.9% | |
| Q4 2018 | -4.9% | -10.8% | -30.1% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro